Ocumetics Technology Corp (NEO:OTC) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of units Closed: C$3.11M raised · C$0.4 a unit · 1 warrant at C$0.5 for 36 months · Ventum Financial Corp. +1 Dealers: Ventum Financial Corp. (finder), Canaccord Genuity Corp. (finder) Use of proceeds: First-in-human clinical trials, ongoing research and development and general working capital | Aug 24, 2026 | |
| Not stated Update: raise Use of proceeds: Fund completion of the first-in-human clinical study and support manufacturing, regulatory and commercialization activities | Jul 9, 2026 | |
| Private placement of units Announced: up to C$1.54M · C$0.55 a unit · 1 warrant at C$0.75 for 36 months Use of proceeds: First in-human clinical trials, ongoing research and development, and general working capital | Apr 29, 2026 | US$1.13M |
| Private placement of units Closed: C$1.02M raised · C$0.6 a unit · 1 warrant at C$0.75 for 36 months · Centurion One Capital Corp. Dealers: Centurion One Capital Corp. (lead) Buyers: Dean Burns; Roger Jewett; Garth Webb; Doyle Stulting; J. Barton McRoberts; Michael Edwards Insiders: Directors Dean Burns (CEO), Roger Jewett (CFO), Garth Webb, Doyle Stulting, J. Barton McRoberts and Michael Edwards participated; related party transaction under MI 61-101 Use of proceeds: First-in-human clinical trials, ongoing research and development and general corporate purposes | Feb 10, 2026 | |
| Private placement of units Tranche closed: C$235,450 raised · C$0.6 a unit · Warrants at C$0.75 · Centurion One Capital Corp. Dealers: Centurion One Capital Corp. | Jan 2, 2026 | US$171,398 |
| Private placement of units Closed: C$1.12M raised · C$0.35 a unit · ½ warrant at C$0.5 for 24 months · Numus Capital Corp. Dealers: Numus Capital Corp. Buyers: Michael Edwards Insiders: Michael Edwards, a director of the Corporation, participated in the Private Placement. Use of proceeds: Ongoing research and development | Aug 12, 2025 |